^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    1d
    NCI-2018-01648: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Rahul Aggarwal | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    1d
    Application of [⁶⁸Ga]DPI-4452 PET/CT in the diagnosis of clear cell renal cell carcinoma and monitoring therapeutic response to targeted-immunotherapy (ChiCTR2600121783)
    P2, N=0, Recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New P2 trial
    2d
    Research on Comprehensive Pedigree Analysis of the Tumor Microenvironment (ChiCTR2600118636)
    P=N/A, N=785, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    2d
    Novel Low-Dose Radioactive Drug（177Lu-R10306）: An Imaging Observation Study on Safety and In Vivo Distribution in Patients with Advanced Cancer (ChiCTR2600118646)
    P1, N=32, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P1 trial
    2d
    Prospective, multi-center, single-arm phase II clinical study of the efficacy and safety of vorolanib monotherapy as adjuvant treatment in intermediate-high risk resectable renal cell carcinoma (ChiCTR2600119252)
    P2, N=200, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New P2 trial
    |
    Fumena (vorolanib)
    3d
    TFAM promotes mitochondrial division by increasing mitochondrial Sirt3. (PubMed, Cell Death Dis)
    Analysis of TCGA data showed that high TFAM-SIRT3 co-expression is associated with overall survival across cancers, particularly in Kidney Renal Clear Cell Carcinoma (KIRC), where TFAM is downregulated (whereas SIRT3 is not). Together, these findings demonstrate that TFAM promotes mitochondrial fission via direct interaction with Sirt3, thereby activating the AMPK/MFF/Drp1 pathway.
    Journal
    |
    SIRT3 (Sirtuin 3) • TFAM (Transcription Factor A, Mitochondrial)
    |
    dorsomorphin (Compound C)
    3d
    Single-Cell Sequencing Plus Spatial Transcriptomics: Dissecting Tumor Heterogeneity, Immunosuppression, and Potential Targets for ASPSCR1::TFE3 Renal Cell Carcinoma. (PubMed, Am J Pathol)
    Moreover, the interaction between tumor cells and macrophages mediated by MDK-LRP1 led to its immune escape.This study confirms that ASPSCR1::TFE3 RCC is a malignant tumor with immunosuppressive features and high metastatic potential, characterized by the enrichment of the C3 subgroup and elevated MDK expression. It provides new insights for the clinical targeted therapy of ASPSCR1::TFE3 RCC and is expected to expand the population of beneficiaries of immunotherapy.
    Journal • IO biomarker
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • LRP1 (LDL Receptor Related Protein 1) • MDK (Midkine) • MMP7 (Matrix metallopeptidase 7)
    3d
    Development and preclinical evaluation of NYM074 as a novel Theranostic ligand targeting carbonic anhydrase IX in renal cell carcinoma. (PubMed, Bioorg Chem)
    NYM074-based radiopharmaceuticals enable rapid, high-contrast CAIX-targeted PET imaging and potent radionuclide therapy, with excellent tolerability in OS-RC-2 model mice. These findings support NYM074 as a promising CAIX-directed theranostic agent for clinical translation in ccRCC.
    Preclinical • Journal
    |
    CA9 (Carbonic anhydrase 9)
    4d
    Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case. (PubMed, Cureus)
    The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg)...ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management.
    Journal
    |
    CA9 (Carbonic anhydrase 9) • MME (Membrane Metalloendopeptidase) • PAX8 (Paired box 8)
    |
    sunitinib
    4d
    PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. (PubMed, Am J Cancer Res)
    We identify a link between IL-6 expression and PIM1 expression and activity in human ccRCC tumors and cell lines. Our work provides evidence that targeting an IL-6/JAK/STAT/PIM1 axis may be a viable therapeutic strategy for patients with PIM1-high expressing ccRCC.
    Journal
    |
    IL6 (Interleukin 6) • PIM1 (Pim-1 Proto-Oncogene)
    |
    Jakafi (ruxolitinib)
    4d
    COSTAR-002: CAIX PET/ CT Guided Radiation Therapy in CcRCC. (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Peking University First Hospital
    New trial
    |
    CA9 (Carbonic anhydrase 9)